In contrast, the efficacy of combined aCD40 and ICB treatment required both CD4 + and CD8 + T cells along with cDC1s for primary tumor rejection, highlighting the cooperative nature of these immune populations in mediating maximal therapeutic responses in the context of combination immunotherapy. This evidence concerns the gene CD8A and neoplasm.